XML 64 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue Interest Financing Payable - Terms (Details) - USD ($)
$ in Thousands
2 Months Ended 12 Months Ended
Oct. 28, 2022
Dec. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Revenue Interest Financing Payable        
Professional fees   $ 1,417 $ 1,417 $ 1,311
Total issuance costs   2,579 $ 2,600  
Estimated effective annual interest rate, percentage     19.00%  
Each calendar quarter from and after the Closing Date through and including the quarter ended June 30, 2026 | Sagard Healthcare Partners        
Revenue Interest Financing Payable        
Quarterly payments expressed as a percentage of the U.S. net sales of Ztalmy and all other pharmaceutical products that contain ganaxolene, required under the revenue interest financing agreement. 7.50%      
Revenue Interest Financing Agreement | Oaktree Capital Management LP Credit Agreement        
Revenue Interest Financing Payable        
Minimum cash and cash equivalents required to be maintained deposits until repayment $ 15,000      
Minimum cash and cash equivalents required to be maintained deposits after repayment 10,000      
Revenue Interest Financing Agreement | Sagard Healthcare Partners        
Revenue Interest Financing Payable        
Investment amount $ 32,500      
Hard Cap expressed as a percentage of the Investment Amount 190.00%      
Hard cap amount $ 61,800      
Professional fees   $ 2,600 $ 2,600  
Revenue Interest Financing Agreement | Each calendar quarter from and after the Closing Date through and including the quarter ended June 30, 2026 | Sagard Healthcare Partners        
Revenue Interest Financing Payable        
Quarterly payments due, expressed as a percentage of the first $100 million in annual Product Revenue of the Included Products 15.00%      
Quarterly payments due, expressed as a percentage of the annual Product Revenue of the Included Products in excess of $100 million 7.50%      
Annual Product Revenue Threshold $ 100,000      
Revenue Interest Financing Agreement | Period Ending December 31, 2027 | Sagard Healthcare Partners        
Revenue Interest Financing Payable        
Minimum amount expressed as a percentage of the Investment Amount 100.00%      
Revenue Interest Financing Agreement | Period Ending December 31, 2032 | Sagard Healthcare Partners        
Revenue Interest Financing Payable        
Minimum amount expressed as a percentage of the Investment Amount 190.00%      
Revenue Interest Financing Agreement | On Or Before Third Anniversary        
Revenue Interest Financing Payable        
Payments at repurchase price investment percent 160.00%      
Revenue Interest Financing Agreement | After Third Anniversary        
Revenue Interest Financing Payable        
Payments at repurchase price investment percent 180.00%      
Royalty monetization agreement | After Fourth Anniversary        
Revenue Interest Financing Payable        
Payments at repurchase price investment percent 190.00%